Nuance Pharma Initiates the First Patient Dosing of Ensifentrine in P-III for the Treatment of Chronic Obstructive Pulmonary Disease
Shots:
- The company dosed the first patient with Ensifentrine in the P-III clinical trial (ENHANCE) evaluating patients with COPD across mainland China. The trial evaluates Ensifentrine as a maintenance treatment for COPD
- Previously in Mar 2023, Nuance completed the first patient dosing of Ensifentrine in the P-I clinical trial evaluating its safety & tolerability in healthy Chinese volunteers
- Ensifentrine is a selective dual inhibitor of PDE3 & PDE4 enzymes that combines bronchodilator & non-steroidal anti-inflammatory activity in a single substance with the ability to reduce respiratory symptoms (such as breathlessness & cough) and has anti-inflammatory properties
Ref: PR Newswire | Image: Nuance Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
